Objectives: Cationic antimicrobial peptides (CAPs) are the effector molecules of innate immunity, similar in potency to classic antibiotics that function in the first-line of defence against infectious agents. The purpose of this study was to investigate the effects of negatively charged mucins on the antibacterial activity of the positively charged cathelicidin LL-37 peptide, its synthetic analogue WLBU2 and the antimicrobial cationic steroid CSA-13.
Introduction
Cationic antimicrobial peptides (CAPs) are widely expressed in the skin, mouth, airways, digestive tract and genitourinary system as an important component of complex secretions, acting synergistically to prevent infection and to control resident microbial populations. 1 -5 Saliva contains a range of CAPs including a-and b-defensins, the cathelicidin-derived LL-37 peptide, histatins and secretory leukocyte protease inhibitor. Most of these agents are synthesized in salivary glands and duct cells or are released by neutrophils. 6 -9 LL-37 peptide is proteolytically processed from human cathelicidin, hCAP-18, which is secreted following cell stimulation and cleaved extracellularly by proteinase-3 or neutrophil elastase. 10 LL-37 acts directly as an antimicrobial 11 against periodontopathogenic and cariogenic bacteria, 12 functions as an immunomodulatory molecule, 13 neutralizes lipopolysaccharide (LPS) bioactivity 14 and acts as a cell membrane receptor agonist stimulating epithelial cell proliferation, angiogenesis, wound healing and cytokine release. 1, 15 At mucosal surfaces of healthy individuals, LL-37 can be detected at concentrations of 2 -5 mg/mL, but during infection, its concentration increases 400% to 500%. 16 The importance of salivary CAPs becomes apparent in patients with severe congenital neutropenia ('Morbus Kostmann') suffering from deficiency of saliva LL-37 and other neutrophil-derived molecules that result in a high occurrence of periodontal disease.
Similarly, significantly lower levels of a-defensins were observed in children with caries, 2 suggesting that CAPs are important factors controlling the growth of microorganisms in the oral cavity. 19 Among the salivary proteins, mucins are primarily responsible for the lubricating and film-forming properties of saliva. 20, 21 They are complex glycoproteins synthesized in epithelial cells and are typically characterized by large molecular weight (2 -20 Â 10 5 Da). Terminal carboxyl groups of sialic acid and sulphates on galactose or N-acetylglucosamine moieties impart negative charges and confer rigidity to mucins. 22 Upon bacterial neuraminidase and sulphatase action, sialic acids and sulphate residues can be removed from mucin unmasking underlying sugars to further enzymatic attack, promoting mucin degradation. This process can cause dysfunction of the mucosal barrier and represents an important step during bacterial invasion. Epithelial cells subjected to the bacterial wall products, LPS or lipoteichoic acid, increase the expression of hCAP-18/ LL-37 and mucin, 23 indicating that at sites of infection, inducible CAPs may function in the presence of increasing mucin concentrations. Charge-based interactions between CAPs and negatively charged polyelectrolytes such as DNA, F-actin, mucins and exopolysaccharides were previously shown to interfere with CAPs' bacterial killing activities. 24 -26 The purpose of this study was to investigate the influence of negatively charged mucins on the antibacterial activities of positively charged LL-37 and WLBU2 peptides, and the ceragenin CSA-13. In vitro assays show that LL-37 is present in saliva and interacts with salivary mucin. This interaction inhibits the antibacterial function of LL-37 and is reversed by treatment of mucin with neuraminidase. Ceragenin CSA-13 antibacterial activity is more resistant to inhibition by mucins when compared with LL-37 and WLBU2 peptides.
Materials and methods

Antibacterial agents
LL-37, rhodamine-B-labelled LL-37 (RhB-LL-37) and WLBU2 were purchased from Bachem (King of Prussia, PA, USA). CSA-13 was prepared as described previously 27 (Table 1) . Stock solutions of antibacterial molecules were prepared in PBS.
Saliva collection
Unstimulated whole saliva was collected by the spitting method from healthy donors aged 20-28 years, between 8 and 11 AM. All subjects had refrained from eating or drinking for 2 h prior to collection. Samples used for the killing assay were centrifuged at 1000 g for 5 min at 48C, and the resulting clarified supernatant fluid was dialysed against PBS using Slide-A-Lyzer dialysis cassettes (20000 MWCO, Pierce, Rockford, IL, USA) to eliminate endogenous low molecular weight saliva factors with antibacterial activity. The study was approved by Medical University of Bialystok Ethics Committee for Research on Humans and Animals, and written consent was obtained from all subjects.
Optical microscopy
Saliva samples were viewed using a Leica microscope (Leica Microsystems Inc., Bannockburn, IL, USA) with a 40Â objective. Images were acquired using a Cool SNAP (HQ) camera (Trenton, NJ, USA). Mucin was labelled using Texas Red-conjugated Ulex europaeus lectin (Sigma, St Louis, MO, USA), as described previously. 28 DNA was labelled with YOYO-1 (Molecular Probes, Boulder, CO, USA) and F-actin was labelled with rhodamine (TRITC) phalloidin (Sigma). In addition to visualizing stained DNA and F-actin, a pattern of fluorescence was also acquired after incubation of saliva samples with RhB-LL-37 (1 mM) for 5 min.
Immunoblot analysis
Samples of saliva were added to gel sample buffer (62.5 mM TrisHCl, pH 6.8; 2% SDS, 25% glycerol, 0.01% Bromophenol Blue, protease inhibitor cocktail 150 mL/10 mL), boiled for 10 min and subjected to electrophoresis on a 16.5% Tris-Tricine SDS-PAGE peptide analysis gel from Bio-Rad (Philadelphia, PA, USA) for LL-37 peptide analyses. After electrophoresis, proteins were transferred to nitrocellulose membranes (Immobilon-NC, Millipore) that were blocked by incubation in 5% (w/v) non-fat dry milk dissolved in TTBS (150 mM NaCl, 50 mM Tris, 0.05% Tween 20, pH 7.4). After transfer to the membrane, proteins were probed for 1 h with a monoclonal anti-LL-37/hCAP-18 antibody (clone 1-1C12, 1:250 dilution, HyCult Biotechnology, Canton, MA, USA) in TTBS. horseradish peroxidase (HRP)-conjugated secondary antibodies were used at a 1:20 000 dilution in TTBS. Immunoblots were developed with the Kodak BioMax MR film using an HRP-targeted chemiluminescent substrate. The relative amount of LL-37 peptide and For amino acids, the one-letter code is used.
hCAP-18 protein in each lane was determined by gel densitometry, followed by image analysis with ImageQuant software.
Binding of rhodamine-B-labelled LL-37 peptide to mucin
To evaluate whether mucin binds LL-37, we performed a binding assay based on previously described techniques. 29 Flat-bottomed multi-well polystyrene plates were coated with: (i) mucins; (ii) mucins treated with neuraminidase type V from Clostridium perfingens; or (iii) neuraminidase by itself. Treatment of mucins with neuraminidase was performed by incubation of 0.2 mg of mucin and 10 U of neuraminidase mixed in 1 mL of 15 mM phosphate buffer, pH 5.0 for 5 h at 378C under agitation. After protein attachment (1 h at 378C), plates were washed with PBS/0.1% Tween 20 and blocked with 0.1% BSA, and the RhB-LL-37 peptide (5 mL of 1 mM stock solution) was added to each well alone or with LPS from Escherichia coli (E. coli) serotype O26:B6 (5 mL of 2 mg/mL solution/well). After 1 h of incubation, plates were washed and the binding of RhB-LL-37 peptide was detected fluorimetrically (I ex ¼ 544/I em ¼ 590), using a multiple plate reader (Fluoroskan Ascent FL, Labsystems Inc., MA, USA).
Antimicrobial activity
The bactericidal activities of LL-37, RhB-LL-37 and WLBU2 peptides and ceragenin CSA-13 in the presence of mucin from bovine submaxillary glands (Sigma) and/or human saliva were measured as described previously. 30 Kanamycin-resistant Pseudomonas aeruginosa (PAO1) and E. coli MG1655 were grown to mid-log phase at 378C (controlled by the evaluation of optical density at 600 nm) and resuspended in PBS buffer. The bacterial suspensions were then diluted 10 times in 100 mL of solutions containing antibacterial agents by themselves or with mucin (1 -1000 mg/mL) or with saliva (20% or 50%). After a 1 h incubation at 378C, the suspensions were placed on ice and diluted 10-to 1000-fold; 10 mL aliquots of each dilution were spotted on Pseudomonas isolation agar containing 25 mg/mL kanamycin or Luria-Bertani broth (LB) agar plates for overnight culture at 378C. The number of colonies at each dilution was counted the following morning. The cfu/mL of the individual samples were determined from the dilution factor. To evaluate the presence of bacteria in saliva samples that may potentially grow on agar used in this assay and interfere with evaluated cfu, saliva after centrifugation was spotted on Pseudomonas isolation agar containing kanamycin or LB agar. Those controls revealed a lack of any bacterial growth.
Evaluation of MICs
The MIC of antibacterial agents was determined by a microbroth dilution method with Mueller -Hinton broth (MHB), 31 with and without the addition of mucin, mucinsþneuraminidase or neuraminidase by itself. Bacteria were grown to mid-log phase at 378C (an optical density of 0.35 at 600 nm) and used at a final concentration of 10 6 cfu/mL (10 mL of bacteria inoculated into 10 mL of MHB). A series of 2-fold dilutions of LL-37, WLBU2 or CSA-13 was prepared from a stock solution and placed in 96-well plates. Dilutions of P. aeruginosa PAO1 or E. coli MG1655 bacteria were then added. After incubation for 18 h at 378C, the bacterial concentration was measured as optical density at 595 nm, and the MIC was read as the lowest concentration resulting in the inhibition of detectable bacterial growth.
Results
Visualization of mucin, DNA and F-actin in saliva
The addition of Texas-Red-conjugated lectin or RhB-LL-37 to saliva samples produced high-intensity labelling without any detectable cellular structures. The similarity of rhodamine B fluorescence patterns with those of lectin labelling indicates the ability of the LL-37 peptide to interact with mucin networks. Labelling with YOYO-1 or fluorescent phalloidin that binds DNA and F-actin, respectively, confirmed the presence of both polymers in saliva, but likely at much lower concentrations. DNA and F-actin are present as point-like structures that are more dense and larger in the case of DNA (Figure 1) . The fluorescence intensity of lectin labelling indicates higher mucin concentrations in saliva when compared with DNA and F-actin.
Immunoblotting analysis of LL-37 in saliva Figure 2 shows results from immunoblotting analyses of three different human saliva samples with anti-LL-37/hCAP-18 antibodies. The analysis revealed that hCAP-18 protein and LL-37 peptide are constituents of saliva, as reported previously. 7 Densitometry of the blots with ImageQuant software showed that LL-37 levels in saliva are ,10% of the level of hCAP-18 protein. In equal volumes of saliva, a detectable heterogeneity of hCAP-18 and LL-37 peptide concentrations exists among different subjects (data not shown).
Mucin binds to LL-37 peptide
Measurements of RhB-LL-37 bound to multi-well plates coated with mucin indicate that mucins may selectively bind LL-37 peptides (Figure 3) . Treatment of mucin with neuraminidase to hydrolyse N-acetyl-neuraminic acid residues from glycoproteins decreased LL-37 peptide binding. A previous study in which neuraminidase-treated mucin, derived from the bovine submaxillary gland, was found to lose its sialic-acid-mediated ability to bind a Clostridial toxin 32 is consistent with the current finding that the negative charge of sialic acid moieties linked to mucin determines mucin's ability to interact with the cationic LL-37 peptide. Binding of LL-37 to mucin was also inhibited by bacterial endotoxin, indicating a possible competition between mucins and LPS for binding LL-37.
Mucins inhibit antibacterial activity of LL-37, WLBU2 and CSA-13 to different extents
The antibacterial activities of LL-37, WLBU2 and CSA-13 against P. aeruginosa PAO1 and E. coli MG1655 were compromised when tested using a bacterial killing assay in the presence of mucin from bovine submaxillary glands, but the magnitude of the effect was significantly less for CSA-13 (Figure 4) . At the same mucin concentration: antibacterial agent ratio, the bacterial killing activity of CSA-13 was more resistant to inhibition by mucin compared with LL-37 and WLBU2 peptides. The ability of mucin to inhibit bactericidal activity was also decreased by neuraminidase (Table 2) . LL-37 peptide labelled with rhodamine B at the N-terminus has activity equal to that of non-labelled LL-37. 33 Consistent with previous results, we observed similar antibacterial activity of rhodamine-B-labelled and non-labelled LL37 peptides against P. aeruginosa PAO1 and E. coli MG1655, and both of them were inhibited by mucin (1 mg/mL) to the same extent (data not shown).
Antibacterial activity of LL-37, WLBU2 and CSA-13 in the presence of human saliva Human saliva contains multiple antibacterial factors, including lysozyme ($14 kDa), secretory leucocyte protease inhibitor ($12 kDa), a-and b-defensins ($10 kDa), LL-37 peptide ($4 kDa) and histatins ($3 kDa), that kill different microorganisms, and their effect may be potentiated by synergistic and additive interaction. 12, 34 As the presence of these molecules may interfere with the evaluation of saliva's effect on the antibacterial activity of synthetic LL-37, WLBU2 and CSA-13, saliva samples used to perform this evaluation were dialysed to remove endogenous antibacterial agents. As shown in Figure 5 , increasing concentrations of human saliva compromised bacterial killing activity of antibacterial agents, but the inhibitory effect decreased in the following order LL37.WLBU2.CSA-13.
Discussion
Decreased LL-37 antibacterial activity in the presence of saliva and host mucins isolated from submaxillary glands indicate that in the oral cavity and other mucin-containing environments, CAPs' bacterial killing activity will not correlate with their concentration. From a functional point of view, both mucins and CAPs are members of the immune system that appear to influence the activity of each other. 25 At physiological pH, CAPs and mucins have opposite charges that promote their electrostatic interaction. 35 This interaction can concentrate antibacterial factors in the thin layer containing mucins, but within that layer, the antibacterial activity is reduced with respect to the antibacterial potency in simple solutions. A crucial factor that determines the strength of counterions (such as LL-37) interaction with polyelectrolytes (such as mucins) is the spacing of charges within the multivalent ion. A recent study showed that as univalent positive-charged groups were increasingly separated from each other by placing methylene spacers between multiple amino groups, the divalent cations eventually lost their ability to aggregate polyelectrolytes and functioned more like multiple monovalent ions. 36 The importance of spacing charges over a polyvalent counterion to avoid condensation of linear polyelectrolytes was the rationale for designing antibacterial molecules that enhance resistance to inactivation by F-actin and DNA. Accordingly, the antibacterial activity of the non-peptide antibacterial molecule CSA-13, a member of the ceragenin family 37 that has a smaller net charge and unique distribution of this charge over a hydrophobic scaffold when compared with natural CAPs, was found to be less inhibited by polyelectrolytes. 
LL-37 peptide binds mucins
Similarly, in the current study, the inhibitory effect of mucin on CSA-13 bactericidal activity was less pronounced when compared with its effect on LL-37 or WLBU2 peptides. The ability of CSA-13 to maintain its antibacterial function in the presence of mucin in addition to DNA/F-actin 38 and its broad-spectrum activities against multidrug-resistant bacteria such as clinical isolates of vancomycin-resistant Staphylococcus aureus 37 and clinical isolates of P. aeruginosa, including multidrug-resistant P. aeruginosa, 39 suggest its potential in treating a range of infections.
The extrinsic mucosal barrier composed of mucins, immunoglobulins and various antibacterial molecules prevents host colonization by a number of microorganisms. In order to breach this barrier, bacteria produce a range of enzymes that, by synergistic action, are capable of partial or complete mucin degradation. 40, 41 Some pathogens express sialic acid units on their surfaces, mimicking the sialyl-rich mucin layer coating epithelial cells and glycoconjugates present on host cell surfaces and serum proteins that function as anti-recognition molecules to escape host immune mechanisms. The presence of sialic acid on bacterial surfaces may significantly impact host -pathogen interaction, leading to immune tolerance. 42 Our finding that inhibition of the antibacterial activity of LL-37 by mucins was reversed upon neuraminidase treatment suggests some important features of the mucosal barrier. First, the ability of mucin to bind CAPs would increase their concentration at the mucosal barrier, a location where these molecules should be present to effectively prevent bacterial invasion. Second, although mucin -LL-37 binding results in the partial loss of LL-37's bacterial killing activity, the release of LL-37 trapped in mucin networks upon bacterial enzyme digestion of mucin would restore the antimicrobial activity of LL37. Third, even if the antibacterial activity of LL-37 peptide decreases when bound to mucins, it is possible that its hormonal activity as a growth factor 43, 44 is maintained. Fourth, during bacterial invasion, cathelicidins and/or LL-37 concentrated within a thin layer at the mucin surface can be processed to shorter forms with enhanced activity and decreased binding, distinct from the LL-37 peptide. 45, 46 These points underline the complexity of mechanisms in the mucosal barrier that hinder microorganism attack. Previous studies that support these speculations include immunohistochemical analysis of LL-37 in human gastric mucosa that showed staining throughout the gastric tubular units, generative zone and mucins, 47 and evidence of a-helical structure of LL-37 upon interaction with mucins, 25 a process previously observed when LL-37 interacts with bacterial wall moieties. 48 In conclusion, the present data shows that the interaction of three cationic antibacterial agents with mucin results in various degrees of inhibition of their antibacterial activity, an effect that was prevented by removing sialic acid from mucin with neuraminidase. The ceragenin CSA-13 is more resistant to inhibition by either purified mucins or whole saliva when compared with the peptides LL-37 and WLBU2, suggesting its possible application in the treatment of oral infection.
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